Targeting IL-17A for Treatment-Resistant Depression

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT04979910
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Ixekizumab — DRUG
    a monoclonal antibody (mAb) against interleukin 17A (IL-17A)

Study Details

The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).

Key Dates

Start date
Aug 27, 2021
Status verified
May 2025
Primary completion
Apr 12, 2024
Completion
Apr 12, 2024

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ixekizumab
    Ixekizumab 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2 and 4 via subcutaneous route.

Primary Outcome Measure

Number of Participants Who Dropped-out [ Time Frame: 6 weeks ]

Locations (1)

FacilityCityStateZIP
Icahn School of Medicine at Mount SinaiNew YorkNew York10025

Related coverage on Hipa.ai

Find similar trials in New York, NY

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies